We are live on
!
Find out more
CM
Crestline Management Portfolio holdings
AUM
$46.3M
1-Year Est. Return
48.82%
This Fund
S&P 500
This Quarter
Est. Return
+25.68%
1 Year Est. Return
+48.82%
3 Year Est. Return
+52.52%
5 Year Est. Return
+37.91%
10 Year Est. Return
+316.44%
AUM
$746M
AUM Growth
+$200M
(+37%)
Cap. Flow
+$60.8M
Cap. Flow
% of AUM
8.15%
Top 10 Holdings %
Top 10 Hldgs %
76.52%
Holding
190
New
78
Increased
30
Reduced
20
Closed
61
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MON
Monsanto Co
MON
|
+$6.18M |
| 2 |
Verisk Analytics
VRSK
|
+$5.61M |
| 3 |
Air Products & Chemicals
APD
|
+$4.62M |
| 4 |
DNB
Dun & Bradstreet
DNB
|
+$4.57M |
| 5 |
Honeywell
HON
|
+$4.05M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FNB Corp
FNB
|
+$5.19M |
| 2 |
Dover
DOV
|
+$4.9M |
| 3 |
Associated Banc-Corp
ASB
|
+$3.9M |
| 4 |
KeyCorp
KEY
|
+$3.73M |
| 5 |
PACW
PacWest Bancorp
PACW
|
+$2.93M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 12.55% |
| 2 | Healthcare | 6.08% |
| 3 | Industrials | 5.43% |
| 4 | Materials | 3.1% |
| 5 | Technology | 1.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Generac Holdings
GNRC
$11.6B
| $1.71M | 0.23% |
47,294
-42,045
| -47% | -$1.5M |
|
52
Exponent
EXPO
$3.24B
| $1.66M | 0.22% |
56,900
-912
| -2% | -$27.3K |
|
53
W.R. Berkley
WRB
$26.9B
| $1.57M | 0.21% |
+76,488
| New | +$1.55M |
|
54
Ingersoll Rand
IR
$32.6B
| $1.56M | 0.21% |
+72,147
| New | +$1.61M |
|
55
Arch Capital
ACGL
$34.3B
| $1.51M | 0.2% |
+48,606
| New | +$1.54M |
|
|
NDRM
56
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $1.51M | 0.2% |
50,468
+32,468
| +180% | +$841K |
|
|
WMGI
57
DELISTED
Wright Medical Group Inc
WMGI
| $1.48M | 0.2% |
53,877
+39,677
| +279% | +$1.12M |
|
|
AHL
58
DELISTED
ASPEN Insurance Holding Limited
AHL
| $1.46M | 0.2% |
+29,221
| New | +$1.48M |
|
59
Willis Towers Watson
WTW
$31.7B
| $1.44M | 0.19% |
+9,917
| New | +$1.39M |
|
|
SHPG
60
DELISTED
Shire pic
SHPG
| $1.44M | 0.19% |
8,706
+306
| +4% | +$53.5K |
|
61
Nasdaq
NDAQ
$52.7B
| $1.43M | 0.19% |
+59,964
| New | +$1.38M |
|
62
East-West Bancorp
EWBC
$17.9B
| $1.39M | 0.19% |
23,800
-12,000
| -34% | -$661K |
|
|
NUVA
63
DELISTED
NuVasive, Inc.
NUVA
| $1.39M | 0.19% |
+18,022
| New | +$1.35M |
|
64
Ingevity
NGVT
$2.54B
| $1.38M | 0.19% |
24,056
+4,629
| +24% | +$272K |
|
65
Puma Biotechnology
PBYI
$404M
| $1.37M | 0.18% |
15,685
+2,785
| +22% | +$156K |
|
|
FSTX
66
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| $1.33M | 0.18% |
+24,645
| New | +$1.14M |
|
67
Rigel Pharmaceuticals
RIGL
$681M
| $1.29M | 0.17% |
+47,169
| New | +$1.29M |
|
|
KDNY
68
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $1.25M | 0.17% |
21,990
+7,770
| +55% | +$390K |
|
|
HEES
69
DELISTED
H&E Equipment Services
HEES
| $1.25M | 0.17% |
61,071
+17,027
| +39% | +$357K |
|
70
Valvoline
VVV
$4.9B
| $1.22M | 0.16% |
+51,250
| New | +$1.19M |
|
71
Cigna
CI
$73.8B
| $1.21M | 0.16% |
7,209
+109
| +2% | +$17.5K |
|
|
TTPH
72
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $1.15M | 0.15% |
8,070
+5,407
| +203% | +$836K |
|
73
T. Rowe Price
TROW
$23.9B
| $1.14M | 0.15% |
+15,399
| New | +$1.1M |
|
74
Intercontinental Exchange
ICE
$85.6B
| $1.14M | 0.15% |
+17,242
| New | +$1.06M |
|
75
Photronics
PLAB
$1.79B
| $1.14M | 0.15% |
120,956
-25,028
| -17% | -$264K |
|
Similar funds
MCMC
RRC
PCM
NPCM
FCM
EGI
IPHI
SM
Crestline Management's Q2 2017 Portfolio in Review
As of Q2 2017, Crestline Management held 190 positions worth $746M, up 37% from $546M the previous quarter. Its ten largest holdings account for 77% of the portfolio.
Crestline Management deployed $60.8M of net new capital in Q2 2017, opening 78 new positions and adding to 30 existing holdings. Its largest new stake was Monsanto Co: 53,000 shares worth $6.27M.
By sector, the portfolio is most concentrated in Financials at 13% of assets, up from 8% a quarter earlier, followed by Healthcare and Industrials.
On the sell side, the largest reduction was FNB Corp, an estimated $5.19M trimmed.
- Crestline Management's largest Q2 2017 buy was Monsanto Co: 53,000 shares worth $6.27M.
- Crestline Management added most to Honeywell in Q2 2017, an estimated $4.05M increase.
- Crestline Management's biggest Q2 2017 reduction was FNB Corp, cutting an estimated $5.19M.
- Crestline Management fully exited Dover in Q2 2017, selling an estimated $4.9M.
- Crestline Management's ten largest holdings make up 77% of its $746M portfolio in Q2 2017.
- Crestline Management opened 78 new positions and closed 61 in Q2 2017.
- Crestline Management's portfolio value rose 37% quarter-over-quarter to $746M.
Based on Crestline Management's 13F filing for Q2 2017, filed 14 Aug 2017.